Immunic, Inc. (FRA:10VA)

Market Cap	63.28M -28.4%
Revenue (ttm)	n/a
Net Income	-87.83M
EPS	-0.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	4,059
Open	0.5690
Previous Close	0.5700
Day's Range	0.5650 - 0.5690
52-Week Range	0.4350 - 1.3090
Beta	n/a
RSI	40.19
Earnings Date	Feb 26, 2026

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 90
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 10VA

Financial Performance

Financial numbers in USD